<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150108</url>
  </required_header>
  <id_info>
    <org_study_id>SHP634-102</org_study_id>
    <nct_id>NCT03150108</nct_id>
  </id_info>
  <brief_title>Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare how rhPTH(1-84) affects the body between healthy
      adults of Japanese descent and matched, healthy Caucasian adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline-adjusted Cmax of PTH(1-84)</measure>
    <time_frame>30 and 90 minutes (min) Pre-dose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours (h) Post-dose</time_frame>
    <description>Baseline-adjusted maximum observed drug concentration (Cmax) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted Tmax of PTH(1-84)</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted time to reach maximum observed drug concentration (Tmax) of PTH(1-84) in plasma was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted AUC(Last) of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted area under the curve from the time of dosing to the last measurable concentration (AUC(last)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted AUC(0-8) of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted area under the concentration versus time curve from the time of dosing to 8 hours post dose (AUC(0-8)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted AUC(0-inf) of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted area under the concentration versus time curve extrapolated to infinity (AUC(0-inf)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline- Adjusted % of AUC(0-Inf) Extra of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted % of AUC extrapolated from the last measurable concentration to infinity over (AUC(0-Inf)) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted Lambda_z of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted Lambda z associated with the terminal (log-linear) portion of the curve for PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted t1/2 of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted Terminal Half-life (t1/2) of PTH(1-84) in plasma was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted CL/F of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted apparent clearance (CL/F) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted Vdz/F of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Baseline-adjusted apparent volume of distribution (Vdz/F) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Original Cmax of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Original maximum observed drug concentration (Cmax) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Original Tmax of PTH(1-84)</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>The original time to reach maximum observed drug concentration (Tmax) of PTH(1-84) in plasma was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Original AUClast of PTH(1-84) in Plasma</measure>
    <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
    <description>Original area under the curve from the time of dosing to the last measurable concentration (AUClast) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of Albumin-corrected Calcium, Serum Total Calcium and Phosphate Levels After Intake of PTH(1-84)</measure>
    <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
    <description>Area under the curve from the time of dosing to the last measurable concentration of albumin-corrected calcium, serum total calcium and phosphate levels after intake of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEmax After Intake of PTH(1-84) on Albumin-corrected Calcium, Serum Total Calcium and Serum Phosphate Levels</measure>
    <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
    <description>The time to maximum effect (TEmax) of PTH(1-84) on albumin-corrected calcium, serum total calcium and serum phosphate levels were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emax of PTH(1-84) on Albumin-corrected Calcium, Serum Total Calcium and Serum Phosphate Levels</measure>
    <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
    <description>The maximum effect (Emax) of PTH(1-84) on albumin-corrected calcium, serum total calcium and serum phosphate levels were reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration to follow-up (up to 40 days)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Clinical Laboratory Tests Reported as Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,24 h,32 days post-dose Japanese Descents: 30 min pre-dose,24 h post-dose on Days 1,4,7 and 32 days after last dose</time_frame>
    <description>Clinical laboratory tests included hematology, chemistry, and urinalysis. Number of participants with clinically significant changes in clinical laboratory tests reported as TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,1,4,8,24 h,32 days post-dose Japanese Descents: 30 min pre-dose,1,4,8,24 h post-dose on Days 1,4,7 and 32 days after last dose</time_frame>
    <description>Vital signs were obtained while participant was supine. Vital signs included hematology, chemistry, and urinalysis. Number of participants with clinically significant changes in vital signs reported as TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Results Reported as Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,24 h,32 days post-dose Japanese Descents: 30 min pre-dose,24 h post-dose on Days 1,4,7 and 32 days after last dose</time_frame>
    <description>Twelve-lead ECGs were performed in triplicate at each time point. For numeric ECG variables, the mean of the valid values at each time point was taken. Number of participants with clinically significant changes in ECGs reported as TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Positive to Anti-Parathyroid Hormone Antibodies</measure>
    <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,32 days post-dose Japanese Descents: 30 min pre-dose on Days 1,4,7 and 32 days after last dose</time_frame>
    <description>Number of participants who reported positive to anti-parathyroid hormone antibodies were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>Non-Hispanic Caucasians</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants of Japanese Descent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPTH(1-84)</intervention_name>
    <description>25 mcg rhPTH(1-84) SC injection</description>
    <arm_group_label>Participants of Japanese Descent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPTH(1-84)</intervention_name>
    <description>50 mcg rhPTH(1-84) SC injection</description>
    <arm_group_label>Participants of Japanese Descent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPTH(1-84)</intervention_name>
    <description>100 mcg rhPTH(1-84) SC injection</description>
    <arm_group_label>Non-Hispanic Caucasians</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to voluntarily provide written, signed, and dated informed consent as
             applicable to participate in the study.

          -  An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          -  Age 18-65 inclusive at the time of consent. The date of signature of the informed
             consent is defined as the beginning of the screening period. This inclusion criterion
             will only be assessed at the first screening visit.

          -  Subjects must be either:

               -  A subject of Japanese descent born in Japan, who has resided outside of Japan for
                  no longer than 5 years and is of Japanese parentage, defined as having 2 Japanese
                  parents, and 4 Japanese grandparents, all born in Japan.

               -  A non-hispanic, Caucasian subject who has 2 non-hispanic, Caucasian parents and 4
                  non-hispanic, Caucasian grandparents.

          -  Male or nonpregnant, nonlactating female who agrees to comply with any applicable
             contraceptive requirements of the protocol or females of nonchildbearing potential.

          -  Considered &quot;healthy&quot; by the investigator. Healthy status is defined by absence of
             evidence of any active or chronic disease following a detailed medical and surgical
             history, a complete physical examination including vital signs, 12-lead
             electrocardiogram (ECG), hematology, blood chemistry, and urinalysis.

          -  Body mass index between 18.5 and 28 kilogram per square meter (kg/m^2), inclusive,
             with a body weight greater than or equal to (&gt;=) 45 kg (99 pounds [lbs]). This
             inclusion criterion will only be assessed at the first screening visit.

          -  Willing and able to consume standardized meals during the confinement period of the
             study. All subjects will be required to consume the identical meals on study days when
             serial pharmacokinetic (PK) and pharmacodynamic (PD) blood samples are collected.

          -  A clinical safety laboratory parameter of hemoglobin greater than (&gt;) 11.7 gram per
             deciliter (g/dl) (females) or 13.1 g/dl (males) and less than (&lt;) 16 g/dl (females) or
             17.4 g/dl (males) or, if out of this range, deemed not clinically significant by the
             principal investigator.

          -  Total serum calcium within laboratory normal limits.

          -  Serum parathyroid hormone (PTH) levels within laboratory normal limits.

        Exclusion Criteria:

          -  History of any hematological, hepatic, respiratory, cardiovascular, renal,
             neurological or psychiatric disease, gall bladder removal, or current or recurrent
             disease that could affect the action, absorption, or disposition of the
             investigational product, or clinical or laboratory assessments.

          -  Current or relevant history of physical or psychiatric illness, any medical disorder
             that may require treatment or make the subject unlikely to fully complete the study,
             or any condition that presents undue risk from the investigational product or
             procedures.

          -  Known or suspected intolerance or hypersensitivity to the investigational product(s),
             closely-related compounds, or any of the stated ingredients.

          -  Significant illness, as judged by the investigator, within 2 weeks of the first dose
             of investigational product.

          -  Known history of alcohol or other substance abuse within the last year.

          -  Donation of blood or blood products (Example (eg), plasma or platelets) within 60 days
             prior to receiving the first dose of investigational product.

          -  Use of the following prior to administration of investigational product within:

               -  30 days - loop diuretics, lithium, antacids, systemic corticosteroids (medical
                  judgment is required by the investigator. Primarily high doses of systemic
                  corticosteroids [eg, prednisone] should be excluded. Stable doses of
                  hydrocortisone [eg, as treatment for Addison's disease] may be acceptable).

               -  3 months - calcitonin, cinacalcet hydrochloride, treatment with rhPTH(1-84) or
                  N-terminal PTH or PTH-related peptide fragments or analogs.

               -  For females: changes in hormone replacement therapy within 3 months are excluded.
                  Stable (≥3 months) hormone replacement therapy is acceptable.

               -  6 months - fluoride tablets, oral bisphosphonates, methotrexate, growth hormone,
                  digoxin, raloxifene or similar selective estrogen receptor modulators (SERMs).

               -  12 months - intravenous bisphosphonates, drug or alcohol abuse, as determined by
                  the investigator.

          -  Confirmed systolic blood pressure (BP) &gt;39 millimeter of mercury (mmHg) or &lt;89 mmHg,
             and diastolic BP &gt;89 mmHg or &lt;49 mmHg.

          -  Twelve-lead ECG demonstrating measure of time between the start of the Q wave and the
             end of the T wave using Fridericia's formula in an electrocardiogram (QTcF) &gt;450
             milliseconds (msec) at screening. If QTcF exceeds 450 msec, the ECG should be repeated
             2 more times and the average of the 3 QTcF values should be used to determine the
             subject's eligibility.

          -  Positive screen for drugs of abuse at screening or drugs of abuse or alcohol on Day
             -1.

          -  Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
             Female subjects who consume more than 14 units of alcohol per week or 2 units per day.
             (1 alcohol unit=1 beer or 1 wine (5 ounce (oz) per 150 milliliter (mL)) or 1 liquor
             (1.5oz/40 mL) or 0.75 oz alcohol).

          -  Positive human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or
             hepatitis C virus (HCV) antibody screen.

          -  Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing
             products in any form (eg, gum, patch). Ex-users must report that they have stopped
             using tobacco for at least 30 days prior to receiving the first dose of
             investigational product.

          -  Routine consumption of more than 2 units of caffeine per day or subjects who
             experience caffeine withdrawal headaches. (1 caffeine unit is contained in the
             following items: one 6 oz (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one
             12 oz cup of tea, three 1 oz (85 g) chocolate bars. Decaffeinated coffee, tea, or cola
             are not considered to contain caffeine).

          -  Prior screen failure, randomization, participation, or enrollment in this study or
             prior exposure to any exogenous PTH, PTH fragments or analogs.

          -  Current use of any medication (including over-the-counter, herbal, or homeopathic
             preparations; with the exception of hormonal replacement therapy or hormonal
             contraceptives and occasional use of ibuprofen and acetaminophen). Current use is
             defined as use within 14 days of the first dose of investigational product.

          -  History of abnormalities of calcium homeostasis including hyperparathyroidism,
             hypoparathyroidism, hyperthyroidism, osteoporosis, Cushing's syndrome, hypercalcemia,
             hypocalcemia, or any other calcium disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <results_first_submitted>April 30, 2019</results_first_submitted>
  <results_first_submitted_qc>April 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2019</results_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Original</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03150108/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 1</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03150108/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03150108/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at a single center in United States between 19 April 2017 (first participant first visit) and 26 Jun 2017 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 24 participants (12 non-Hispanic healthy volunteer Caucasian participants and 12 healthy Japanese participants) were enrolled and randomized to study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Non-Hispanic Caucasians</title>
          <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Participants of Japanese Descent</title>
          <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1, then followed by either 25 mcg or 50 mcg SC injection on Days 4 and 7 in a cross-over fashion. A washout period of 73 hours was maintained between each single doses (100 mcg, 50 mcg and 25 mcg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
      <group_list>
        <group group_id="B1">
          <title>Non-Hispanic Caucasians</title>
          <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single SC injection of 100 mcg rhPTH[1-84] on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Participants of Japanese Descent</title>
          <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1, then followed by either 25 mcg or 50 mcg SC injection on Days 4 and 7 in a cross-over fashion. A washout period of 73 hours was maintained between each single doses (100 mcg, 50 mcg and 25 mcg).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" spread="9.01"/>
                    <measurement group_id="B2" value="41.3" spread="10.40"/>
                    <measurement group_id="B3" value="40.8" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted Cmax of PTH(1-84)</title>
        <description>Baseline-adjusted maximum observed drug concentration (Cmax) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 minutes (min) Pre-dose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours (h) Post-dose</time_frame>
        <population>The pharmacokinetic (PK) set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians: 100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Cmax of PTH(1-84)</title>
          <description>Baseline-adjusted maximum observed drug concentration (Cmax) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The pharmacokinetic (PK) set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>Picogram per milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295.662" spread="41.66"/>
                    <measurement group_id="O2" value="330.820" spread="29.44"/>
                    <measurement group_id="O3" value="175.468" spread="35.29"/>
                    <measurement group_id="O4" value="99.708" spread="22.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Welch's t-test with Satterthwaite's approximation to the degrees of freedom was used to compare the log transformed Cmax values of both ethnic groups at 100 mcg dose and the results were back-transformed to get the estimates for the geometric means and for the ratio of geometric means (Japanese/Caucasian), and 90% confidence interval (CI).</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.119</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.875</ci_lower_limit>
            <ci_upper_limit>1.430</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was assessed for baseline‑adjusted Cmax using the power model. The power model assumes a linear relationship between the natural log transformed parameter and the natural log transformed dose. The fold increase in PK parameters with doubling the dose and the 90% CIs were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality</non_inferiority_desc>
            <param_type>Increase in Cmax per Dose Doubling</param_type>
            <param_value>1.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
            <estimate_desc>Linear model of log transformed PK parameters at all doses in Japanese descent, including log transformed dose, period, sequence as fixed effects, and intercept as a random effect accounting for each participant within sequence as their own control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted Tmax of PTH(1-84)</title>
        <description>Baseline-adjusted time to reach maximum observed drug concentration (Tmax) of PTH(1-84) in plasma was reported.</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians: 100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Tmax of PTH(1-84)</title>
          <description>Baseline-adjusted time to reach maximum observed drug concentration (Tmax) of PTH(1-84) in plasma was reported.</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>Hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.415" lower_limit="0.17" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.17" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.385" lower_limit="0.50" upper_limit="2.50"/>
                    <measurement group_id="O4" value="1.240" lower_limit="0.17" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted AUC(Last) of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted area under the curve from the time of dosing to the last measurable concentration (AUC(last)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians: 100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted AUC(Last) of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted area under the curve from the time of dosing to the last measurable concentration (AUC(last)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>Hour*picogram per milliliter (h*pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1037.63" spread="31.0"/>
                    <measurement group_id="O2" value="1027.81" spread="32.6"/>
                    <measurement group_id="O3" value="602.06" spread="30.6"/>
                    <measurement group_id="O4" value="255.67" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Welch's t-test with Satterthwaite's approximation to the degrees of freedom was used to compare the log transformed AUClast values of both ethnic groups at 100 mcg dose and the results were back-transformed to get the estimates for the geometric means and for the ratio of geometric means (Japanese/Caucasian), and 90% CI.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was assessed for baseline‑adjusted AUClast using the power model. The power model assumes a linear relationship between the natural log transformed parameter and the natural log transformed dose. The fold increase in PK parameters with doubling the dose and the 90% CIs were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality</non_inferiority_desc>
            <param_type>Increase in AUClast per Dose Doubling</param_type>
            <param_value>2.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>2.06</ci_lower_limit>
            <ci_upper_limit>2.70</ci_upper_limit>
            <estimate_desc>Linear model of log transformed PK parameters at all doses in Japanese descent, including log transformed dose, period, sequence as fixed effects, and intercept as a random effect accounting for each participant within sequence as their own control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted AUC(0-8) of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted area under the concentration versus time curve from the time of dosing to 8 hours post dose (AUC(0-8)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted AUC(0-8) of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted area under the concentration versus time curve from the time of dosing to 8 hours post dose (AUC(0-8)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="956.63" spread="32.8"/>
                    <measurement group_id="O2" value="1033.62" spread="31.4"/>
                    <measurement group_id="O3" value="554.23" spread="30.8"/>
                    <measurement group_id="O4" value="248.38" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Welch's t-test with Satterthwaite's approximation to the degrees of freedom was used to compare the log transformed AUC0-8 values of both ethnic groups at 100 mcg dose and the results were back-transformed to get the estimates for the geometric means and for the ratio of geometric means (Japanese/Caucasian), and 90% CI.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was assessed for baseline‑adjusted AUC0-8 using the power model. The power model assumes a linear relationship between the natural log transformed parameter and the natural log transformed dose. The fold increase in PK parameters with doubling the dose and the 90% CIs were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality</non_inferiority_desc>
            <param_type>Increase in AUC0-8 per Dose Doubling</param_type>
            <param_value>2.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
            <estimate_desc>Linear model of log transformed PK parameters at all doses in Japanese descent, including log transformed dose, period, sequence as fixed effects, and intercept as a random effect accounting for each participant within sequence as their own control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted AUC(0-inf) of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted area under the concentration versus time curve extrapolated to infinity (AUC(0-inf)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians: 100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted AUC(0-inf) of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted area under the concentration versus time curve extrapolated to infinity (AUC(0-inf)) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.29" spread="37.0"/>
                    <measurement group_id="O2" value="1039.34" spread="29.8"/>
                    <measurement group_id="O3" value="589.25" spread="31.6"/>
                    <measurement group_id="O4" value="249.51" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Welch's t-test with Satterthwaite's approximation to the degrees of freedom was used to compare the log transformed AUC0-inf values of both ethnic groups at 100 mcg dose and the results were back-transformed to get the estimates for the geometric means and for the ratio of geometric means (Japanese/Caucasian), and 90% CI.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was assessed for baseline‑adjusted AUC0-inf using the power model. The power model assumes a linear relationship between the natural log transformed parameter and the natural log transformed dose. The fold increase in PK parameters with doubling the dose and the 90% CIs were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality</non_inferiority_desc>
            <param_type>Increase in AUC0-inf per Dose Doubling</param_type>
            <param_value>2.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.96</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
            <estimate_desc>Linear model of log transformed PK parameters at all doses in Japanese descent, including log transformed dose, period, sequence as fixed effects, and intercept as a random effect accounting for each participant within sequence as their own control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline- Adjusted % of AUC(0-Inf) Extra of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted % of AUC extrapolated from the last measurable concentration to infinity over (AUC(0-Inf)) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline- Adjusted % of AUC(0-Inf) Extra of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted % of AUC extrapolated from the last measurable concentration to infinity over (AUC(0-Inf)) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
          <units>Percentage of AUC</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.416" spread="198.59"/>
                    <measurement group_id="O2" value="0.932" spread="330.55"/>
                    <measurement group_id="O3" value="1.555" spread="173.86"/>
                    <measurement group_id="O4" value="3.015" spread="135.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted Lambda_z of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted Lambda z associated with the terminal (log-linear) portion of the curve for PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Lambda_z of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted Lambda z associated with the terminal (log-linear) portion of the curve for PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>Per hour (1/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4496" spread="67.730"/>
                    <measurement group_id="O2" value="0.6672" spread="35.835"/>
                    <measurement group_id="O3" value="0.5714" spread="65.437"/>
                    <measurement group_id="O4" value="0.8277" spread="57.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted t1/2 of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted Terminal Half-life (t1/2) of PTH(1-84) in plasma was reported.</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted t1/2 of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted Terminal Half-life (t1/2) of PTH(1-84) in plasma was reported.</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
          <units>Hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.390" lower_limit="0.68" upper_limit="4.74"/>
                    <measurement group_id="O2" value="1.060" lower_limit="0.65" upper_limit="1.71"/>
                    <measurement group_id="O3" value="1.020" lower_limit="0.69" upper_limit="3.57"/>
                    <measurement group_id="O4" value="0.950" lower_limit="0.30" upper_limit="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted CL/F of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted apparent clearance (CL/F) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted CL/F of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted apparent clearance (CL/F) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
          <units>Liter per hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.25" spread="37.0"/>
                    <measurement group_id="O2" value="96.22" spread="29.8"/>
                    <measurement group_id="O3" value="84.84" spread="31.6"/>
                    <measurement group_id="O4" value="100.18" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted Vdz/F of PTH(1-84) in Plasma</title>
        <description>Baseline-adjusted apparent volume of distribution (Vdz/F) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Vdz/F of PTH(1-84) in Plasma</title>
          <description>Baseline-adjusted apparent volume of distribution (Vdz/F) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value. Here number of participants analyzed indicates the participants evaluable for this outcome.</population>
          <units>Liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.30" spread="93.9"/>
                    <measurement group_id="O2" value="144.18" spread="54.7"/>
                    <measurement group_id="O3" value="148.50" spread="71.9"/>
                    <measurement group_id="O4" value="121.02" spread="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Original Cmax of PTH(1-84) in Plasma</title>
        <description>Original maximum observed drug concentration (Cmax) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Original Cmax of PTH(1-84) in Plasma</title>
          <description>Original maximum observed drug concentration (Cmax) of PTH(1-84) in plasma was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324.43" spread="36.2"/>
                    <measurement group_id="O2" value="365.52" spread="27.3"/>
                    <measurement group_id="O3" value="206.05" spread="29.6"/>
                    <measurement group_id="O4" value="129.74" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Welch's t-test with Satterthwaite's approximation to the degrees of freedom was used to compare the log transformed Cmax values of both ethnic groups at 100 mcg dose and the results were back-transformed to get the estimates for the geometric means and for the ratio of geometric means (Japanese/Caucasian), and 90% CI.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Original Tmax of PTH(1-84)</title>
        <description>The original time to reach maximum observed drug concentration (Tmax) of PTH(1-84) in plasma was reported.</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Original Tmax of PTH(1-84)</title>
          <description>The original time to reach maximum observed drug concentration (Tmax) of PTH(1-84) in plasma was reported.</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>Hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.415" lower_limit="0.17" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.17" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.385" lower_limit="0.50" upper_limit="2.50"/>
                    <measurement group_id="O4" value="1.240" lower_limit="0.17" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Original AUClast of PTH(1-84) in Plasma</title>
        <description>Original area under the curve from the time of dosing to the last measurable concentration (AUClast) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>30 and 90 min Pre-dose,10, 20, 30, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h Post-dose</time_frame>
        <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants (who have 2 non-Hispanic Caucasian parents and 4 non-Hispanic Caucasian grandparents) matched to participants of Japanese descent based on sex (1:1 male: female), age (+/-7 years), and body mass index (+/-15%) received a single subcutaneous (SC) injection of 100 microgram (mcg) recombinant human parathyroid hormone (rhPTH[1-84]) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants (born in Japan, who have resided outside of Japan for no longer than 5 years and were of Japanese parentage, defined as having 2 Japanese parents, and 4 Japanese grandparents, all born in Japan) received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Original AUClast of PTH(1-84) in Plasma</title>
          <description>Original area under the curve from the time of dosing to the last measurable concentration (AUClast) of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PK set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PK concentration value.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1685.62" spread="18.2"/>
                    <measurement group_id="O2" value="1823.70" spread="23.7"/>
                    <measurement group_id="O3" value="1300.09" spread="21.7"/>
                    <measurement group_id="O4" value="959.49" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Welch's t-test with Satterthwaite's approximation to the degrees of freedom was used to compare the log transformed Cmax values of both ethnic groups at 100 mcg dose and the results were back-transformed to get the estimates for the geometric means and for the ratio of geometric means (Japanese/Caucasian), and 90% CI.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast of Albumin-corrected Calcium, Serum Total Calcium and Phosphate Levels After Intake of PTH(1-84)</title>
        <description>Area under the curve from the time of dosing to the last measurable concentration of albumin-corrected calcium, serum total calcium and phosphate levels after intake of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
        <population>The pharmacodynamic (PD) set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PD concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast of Albumin-corrected Calcium, Serum Total Calcium and Phosphate Levels After Intake of PTH(1-84)</title>
          <description>Area under the curve from the time of dosing to the last measurable concentration of albumin-corrected calcium, serum total calcium and phosphate levels after intake of PTH(1-84) was reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The pharmacodynamic (PD) set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PD concentration value.</population>
          <units>Hours * millimoles per liter (h×mmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin-corrected Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.94" spread="2.5"/>
                    <measurement group_id="O2" value="53.22" spread="2.3"/>
                    <measurement group_id="O3" value="52.94" spread="2.5"/>
                    <measurement group_id="O4" value="52.61" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.21" spread="2.7"/>
                    <measurement group_id="O2" value="54.62" spread="1.5"/>
                    <measurement group_id="O3" value="54.12" spread="2.6"/>
                    <measurement group_id="O4" value="53.62" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.21" spread="10.5"/>
                    <measurement group_id="O2" value="28.85" spread="10.2"/>
                    <measurement group_id="O3" value="28.60" spread="7.8"/>
                    <measurement group_id="O4" value="29.57" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TEmax After Intake of PTH(1-84) on Albumin-corrected Calcium, Serum Total Calcium and Serum Phosphate Levels</title>
        <description>The time to maximum effect (TEmax) of PTH(1-84) on albumin-corrected calcium, serum total calcium and serum phosphate levels were reported.</description>
        <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
        <population>The PD set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PD concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>TEmax After Intake of PTH(1-84) on Albumin-corrected Calcium, Serum Total Calcium and Serum Phosphate Levels</title>
          <description>The time to maximum effect (TEmax) of PTH(1-84) on albumin-corrected calcium, serum total calcium and serum phosphate levels were reported.</description>
          <population>The PD set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PD concentration value.</population>
          <units>Hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin-corrected Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="4.00" upper_limit="12.02"/>
                    <measurement group_id="O2" value="8.000" lower_limit="4.00" upper_limit="12.00"/>
                    <measurement group_id="O3" value="4.000" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="4.000" lower_limit="0.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="0.00" upper_limit="12.02"/>
                    <measurement group_id="O2" value="8.000" lower_limit="4.00" upper_limit="12.00"/>
                    <measurement group_id="O3" value="8.000" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="4.000" lower_limit="0.00" upper_limit="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.010" lower_limit="0.00" upper_limit="12.05"/>
                    <measurement group_id="O2" value="8.000" lower_limit="4.00" upper_limit="11.98"/>
                    <measurement group_id="O3" value="8.000" lower_limit="7.97" upper_limit="12.08"/>
                    <measurement group_id="O4" value="8.000" lower_limit="0.00" upper_limit="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emax of PTH(1-84) on Albumin-corrected Calcium, Serum Total Calcium and Serum Phosphate Levels</title>
        <description>The maximum effect (Emax) of PTH(1-84) on albumin-corrected calcium, serum total calcium and serum phosphate levels were reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
        <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
        <population>The PD set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PD concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Emax of PTH(1-84) on Albumin-corrected Calcium, Serum Total Calcium and Serum Phosphate Levels</title>
          <description>The maximum effect (Emax) of PTH(1-84) on albumin-corrected calcium, serum total calcium and serum phosphate levels were reported. The dispersion measure Geometric Coefficient of Variation was reported in percent (%).</description>
          <population>The PD set consisted of participants who received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable post-dose PD concentration value.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin-corrected Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.287" spread="2.31"/>
                    <measurement group_id="O2" value="2.284" spread="2.46"/>
                    <measurement group_id="O3" value="2.283" spread="3.09"/>
                    <measurement group_id="O4" value="2.282" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.359" spread="3.49"/>
                    <measurement group_id="O2" value="2.347" spread="1.83"/>
                    <measurement group_id="O3" value="2.330" spread="2.60"/>
                    <measurement group_id="O4" value="2.322" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.286" spread="11.88"/>
                    <measurement group_id="O2" value="1.325" spread="11.47"/>
                    <measurement group_id="O3" value="1.325" spread="7.94"/>
                    <measurement group_id="O4" value="1.383" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.</description>
        <time_frame>From start of study drug administration to follow-up (up to 40 days)</time_frame>
        <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.</description>
          <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Clinical Laboratory Tests Reported as Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Clinical laboratory tests included hematology, chemistry, and urinalysis. Number of participants with clinically significant changes in clinical laboratory tests reported as TEAEs were reported.</description>
        <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,24 h,32 days post-dose Japanese Descents: 30 min pre-dose,24 h post-dose on Days 1,4,7 and 32 days after last dose</time_frame>
        <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Clinical Laboratory Tests Reported as Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Clinical laboratory tests included hematology, chemistry, and urinalysis. Number of participants with clinically significant changes in clinical laboratory tests reported as TEAEs were reported.</description>
          <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Vital signs were obtained while participant was supine. Vital signs included hematology, chemistry, and urinalysis. Number of participants with clinically significant changes in vital signs reported as TEAEs were reported.</description>
        <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,1,4,8,24 h,32 days post-dose Japanese Descents: 30 min pre-dose,1,4,8,24 h post-dose on Days 1,4,7 and 32 days after last dose</time_frame>
        <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Vital signs were obtained while participant was supine. Vital signs included hematology, chemistry, and urinalysis. Number of participants with clinically significant changes in vital signs reported as TEAEs were reported.</description>
          <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Results Reported as Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Twelve-lead ECGs were performed in triplicate at each time point. For numeric ECG variables, the mean of the valid values at each time point was taken. Number of participants with clinically significant changes in ECGs reported as TEAEs were reported.</description>
        <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,24 h,32 days post-dose Japanese Descents: 30 min pre-dose,24 h post-dose on Days 1,4,7 and 32 days after last dose</time_frame>
        <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Results Reported as Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Twelve-lead ECGs were performed in triplicate at each time point. For numeric ECG variables, the mean of the valid values at each time point was taken. Number of participants with clinically significant changes in ECGs reported as TEAEs were reported.</description>
          <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Positive to Anti-Parathyroid Hormone Antibodies</title>
        <description>Number of participants who reported positive to anti-parathyroid hormone antibodies were reported.</description>
        <time_frame>Non-Hispanic Caucasians: 30 min pre-dose,32 days post-dose Japanese Descents: 30 min pre-dose on Days 1,4,7 and 32 days after last dose</time_frame>
        <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Hispanic Caucasians:100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
          <group group_id="O4">
            <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
            <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Positive to Anti-Parathyroid Hormone Antibodies</title>
          <description>Number of participants who reported positive to anti-parathyroid hormone antibodies were reported.</description>
          <population>The safety set included enrolled participants who received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration to follow-up (up to 40 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-Hispanic Caucasians:100 mcg rhPTH(1- 84)</title>
          <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Participants of Japanese Descent: 100 mcg rhPTH(1-84)</title>
          <description>Participants received a single SC injection of 100 mcg rhPTH(1-84) on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Participants of Japanese Descent: 50 mcg rhPTH(1-84)</title>
          <description>Participants received a single SC injection of 50 mcg rhPTH(1-84) on Day 4 or 7.</description>
        </group>
        <group group_id="E4">
          <title>Participants of Japanese Descent: 25 mcg rhPTH(1-84)</title>
          <description>Participants received a single SC injection of 25 mcg rhPTH(1-84) on Day 4 or 7.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

